Price$3.12-0.15 (-4.74%)
01:45 PM07:45 PM
News · 26 weeks61-62%
2026-04-192026-10-11
Mix3090d
- Insider12(40%)
- Other10(33%)
- SEC Filings5(17%)
- Offering3(10%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by Clene Inc.SCHEDULE 13G/A - Clene Inc. (0001822791) (Subject)
- PRClene to Present at Upcoming Investor ConferencesSALT LAKE CITY, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) today announced that management will participate at the 5th Annual ROTH Healthcare Opportunities Conference and at the Lytham Partners Investor Conference Fall Event and host 1x1 investor meetings at both conferences. 5th Annual ROTH Healthcare Opportunities ConferenceDate: September 29, 2026Location: New York, NYFormat: 1x1 meetings1x1 Meetings: Please contact your ROTH representative Lytham Partners Investor Conference Fall EventDate: September 29-30, 2026Time of Presentation: 9:45 am ETLocation: VirtualFormat: Presentation and 1x1 meetings1x1 Meetings: Please contact your Lytham representativeWebcast: link to
- PRClene Announces Closing of $4 Million Registered Direct Offering Extending Capital Runway Beyond FDA Decision on CNM-Au8® NDAInvestment was led by Clene’s Chairman of the Board of Directors, alongside founding investor Kensington Capital Holdings, Clene’s Chief Executive Officer and other existing shareholders$4 million registered direct offering was priced at market under Nasdaq rulesProceeds are expected to be sufficient to fund the Company to mid-first quarter 2027, which is beyond the potential FDA decision to accept the CNM-Au8® NDA for review under the accelerated approval pathway SALT LAKE CITY, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN), a clinical-stage biotechnology company focused on ALS, today announced the closing of a registered direct offering of common stock to existing shareho
- INSIDERDirector Matlin David J was granted 434,451 shares (SEC Form 4)4 - Clene Inc. (0001822791) (Issuer)
- INSIDERPresident & CEO Etherington Robert Dee was granted 15,244 shares (SEC Form 4)4 - Clene Inc. (0001822791) (Issuer)
- INSIDERDirector Mosca Alison was granted 198,171 shares (SEC Form 4)4 - Clene Inc. (0001822791) (Issuer)
- SECClene Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - Clene Inc. (0001822791) (Filer)
- SECSEC Form 424B5 filed by Clene Inc.424B5 - Clene Inc. (0001822791) (Filer)
- PRClene Announces $4 Million Registered Direct OfferingInvestment led by Clene’s Chairman of the Board of Directors, alongside founding investor Kensington Capital Holdings, Clene’s Chief Executive Officer and other existing shareholders$4 million registered direct offering priced at market under Nasdaq rulesProceeds are expected to be sufficient to fund the Company to mid-first quarter 2027 SALT LAKE CITY, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN), a clinical-stage biotechnology company focused on ALS, today announced the pricing of a registered direct offering of 1,219,513 shares at a purchase price of $3.28 per share to existing shareholders, including insiders, with total gross proceeds of $4 million. The offering is ex
- PRA Micro-Cap Biotech Just Cleared a Milestone Most Never ReachAUSTIN, Texas, Sept. 08, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Multiple sclerosis ("MS") drugs on the market today can slow the disease down, but none of them stop it, and none of them give patients back what they have already lost. Nearly one million people in the United States, and close to 2.9 million worldwide, live with that reality, watching a disease that can gradually erode mobility, vision, and basic bodily control. That gap has just gotten a serious new challenger. Quantum BioPharma Ltd. (NASDAQ:QNTM) (profile) has received FDA clearance to begin a phase 2 trial of Lucid-MS, a patented, first-in-class drug candidate aimed not at calming the immune system but at
- PRClene to Present at Upcoming September Investor ConferencesSALT LAKE CITY, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) today announced that management will present at the 2026 Cantor Global Healthcare Conference and at the H.C. Wainwright 28th Annual Global Investment Conference and host 1x1 investor meetings at both conferences. 2026 Cantor Global Healthcare ConferenceDate: September 9, 2026Time of Presentation: 9:10am ETLocation: New York, NYFormat: Presentation and 1x1 meetings1x1 Meetings: Please contact your Cantor representativeWebcast: link to webcast HC Wainwright 28th Annual Global Investment ConferenceDate: September 15th, 2026Time of Presentation: 1:30pm ETLocation: New York, NYFormat: Presentation and 1x1 meetings1x1
- PRPresenting on Emerging Growth Conference 95 Day 2 on August 20; Register to live streamMIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 95th Emerging Growth Conference on August 19 & 20, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter All times are in Eastern Time Presenting Today – Wednesday August 19, 2026 8:30Virtual Lobby opens.Register for the Con
- PRPresenting on Emerging Growth Conference 95 Day 1 on August 19; Register to live streamMIAMI, Aug. 18, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com, a leading independent small cap media portal, announces the schedule of the 95th Emerging Growth Conference on August 19 & 20, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter All times are in Eastern Time Day 1 - WednesdayAugust 19, 2026 8:30Virtual Lobby opens.Register for the Conference. I
- PRClene to Present at the Emerging Growth ConferenceSALT LAKE CITY, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) today announced that management will present at the Emerging Growth Conference. Virtual Presentation DetailsDate: August 19, 2026Time of Presentation: 3:10 p.m. ETFormat: Corporate update A webcast of the presentation will be available on the "Events" section of the Clene website. Alternatively, one can register for and view the webcast here: https://goto.webcasts.com/starthere.jsp?ei=1764701&tp_key=7a35454f76&sti=clnn. A replay of the presentation will also be available through the conference portal and the Emerging Growth YouTube Channel, http://www.YouTube.com/EmergingGrowthConference, following the event. Abo
- INSIDERSEC Form 4 filed by Director Kiernan Matthew4 - Clene Inc. (0001822791) (Issuer)
- INSIDERSEC Form 4 filed by Director Desai Arjun Jj4 - Clene Inc. (0001822791) (Issuer)
- INSIDERSEC Form 4 filed by Director Mosca Alison4 - Clene Inc. (0001822791) (Issuer)
- INSIDERSEC Form 4 filed by Director Matlin David J4 - Clene Inc. (0001822791) (Issuer)
- INSIDERSEC Form 4 filed by Director Jacobovitz Shalom4 - Clene Inc. (0001822791) (Issuer)
- INSIDERSEC Form 4 filed by Director Gay Jonathon4 - Clene Inc. (0001822791) (Issuer)
- INSIDERSEC Form 4 filed by Director Mclaughlin Vallerie4 - Clene Inc. (0001822791) (Issuer)
- INSIDERSEC Form 4 filed by Director Wilcox Reed N4 - Clene Inc. (0001822791) (Issuer)
- SECClene Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Clene Inc. (0001822791) (Filer)
- PRClene Reports Second Quarter 2026 Financial Results and Recent Operating HighlightsClene expects to submit a New Drug Application for CNM-Au8® in ALS under the accelerated approval pathway in early fourth quarter of 2026Clene announces survival and functional benefit in CNM-Au8-treated patients whose NfL declined or stabilized SALT LAKE CITY, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) today announced its second quarter 2026 financial results and provided recent updates on its CNM-Au8 programs. "We plan to submit our new drug application (NDA) for CNM-Au8 under the accelerated approval pathway for patients with ALS and believe the evidence connecting the magnitude of NfL reduction to clinical benefit data we have generated since our last FDA meeting will
- SECSEC Form 10-Q filed by Clene Inc.10-Q - Clene Inc. (0001822791) (Filer)
CLNN FAQ
6 questionsWhat does Clene Inc. do?
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean surfaced nanotechnology (CSN) therapeutics. The company has a nanotechnology drug suspension; and engages in the development and commercialization of dietary supplements. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2 study for the treatment of stable multiple sclerosis; a Phase 2 biomarker study in Parkinson's; and Phase 2 and Phase 3 trials to investigate the potential for disease modification for neurodegenerative...Where does CLNN stock trade?
Clene Inc. (CLNN) is listed on NASDAQ.What sector and industry is CLNN in?
Clene Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about CLNN?
Clene Inc. has had 4 recent analyst actions on file. The most recent action was from Oppenheimer: Perform on 2022-10-04. Recent price targets range from $1000.00 to $2000.00.What companies are similar to CLNN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare CLNN side-by-side with any of them on Quantisnow.How can I track CLNN on Quantisnow?
Quantisnow aggregates Clene Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CLNN to receive live email and push alerts on every new disclosure.